Oncology_KUNTUO

From breakthrough in laboratories to patients’ hope, clinical trial is the “last one mile” which is the most difficult, expensive and meaningful progress, full of scientific complexity, huge challenges operationally and extreme pursue to speed. The reason why clinical progress of an anticancer drug takes so long is that a perfect balance must be obtained among science rigorousness, patient safety, operational feasibility and development speed. The core value of a partner who puts emphasis on tumor area, like Kun Tuo, is to be the “accelerator” and “stabilizer” for pharmaceutical companies. Our team provides full-cycle and end-to-end services from strategy counseling to actual implementation, turning advanced accelerating strategies into feasible reality, simplifying complex progress to save more time for lives and achieving the speedup of full-cycle solutions.

Kun Tuo can provide complete and “customized” development plans and strategies throughout all life cycles in clinical studies; Kun Tuo’s Medical Affairs and Regulation department have made joint effects on promoting a large number of IND application in both China and US for new antitumor drugs and the preparation and approval of IND in China. Furthermore, our team has contributed significantly to successful launch of various products, which have obtained sustained appreciation from clients and the industry. Thanks to powerful resources of IQVIA, Kun Tuo is able to have efficient internal communication and provide best solutions to clients in a short time as well as support MRCT projects better in a hybrid way with the support of the top-class strategy consultants of oncology from COE team and the guidance of former FDA regulatory affair specialists.